<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140397</url>
  </required_header>
  <id_info>
    <org_study_id>HS-PF1-2016</org_study_id>
    <nct_id>NCT03140397</nct_id>
  </id_info>
  <brief_title>Oral Bioavailability and Bioactivity of Prenylflavonoids From Hops</brief_title>
  <official_title>Examination of the Bioavailability and Bioactivity of the Two Natural Food Ingredients 6-Prenylnaringenin and 8-Prenylnaringenin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hohenheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universität Tübingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hohenheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prenylflavonoids 6-prenylnaringenin (6-PN) and 8-prenylnaringenin (8-PN) are secondary
      plant substances, almost exclusively found in hops (Humulus lupulus). Both compounds have
      known potential biological properties, but poor bioavailability due to their low oral
      absorption and retention. Our study followed a single dose (500 mg 6- or 8-PN), placebo
      controlled, randomized, double-blind, three armed crossover study design with ≥2-week washout
      periods. Plasma, PBMC and urine samples were collected at intervals up to 24 h after intake.
      Investigators investigated the safety, pharmacokinetics and impact of oral prenylflavonoids
      on the function of cells of the immune system.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean area under the curve (AUC) of plasma concentration vs. time of total 6-prenylnaringenin [nmol/L*h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total 6-PN after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the curve (AUC) of plasma concentration vs. time of total 8-prenylnaringenin [nmol/L*h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean maximum plasma concentration (Cmax) of total 6-prenylnaringenin [nmol/L]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean maximum plasma concentration (Cmax) of total 8-prenylnaringenin [nmol/L]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of total 6-prenylnaringenin [h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of total 8-prenylnaringenin [h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative urinary excretion of total 6-prenylnaringenin [nmol/g creatinine]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative urinary excretion of total 8-prenylnaringenin [nmol/g creatinine]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell count (dead cells/ml and living cells/ml) of PBMCs after 6-PN administration</measure>
    <time_frame>0, 6, and 24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell count (dead cells/ml and living cells/ml) of PBMCs after 8-PN administration</measure>
    <time_frame>0, 6, and 24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell viability of PBMCs after 6-PN administration</measure>
    <time_frame>0, 6, and 24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell viability of PBMCs after 8-PN administration</measure>
    <time_frame>0, 6, and 24 h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum aspartate transaminase activity [U/L]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alanine transaminase activity [U/L]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum gamma-glutamyl transferase activity [U/L]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alkaline phosphatase activity [U/L]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bilirubin</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum uric acid [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HDL cholesterol [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LDL cholesterol [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triacylglycerols [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL/HDL cholesterol ratio</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cystatin C [mg/mL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate [mL/min]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose [mg/dL]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin [g/dL]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin concentration [g/dL]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin [pg]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume [fL]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit [%]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocytes [/pL]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombocytes [/nL]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leucocytes [/nL]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Segmented granulocytes [%]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes [%]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes [%]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basophil granulocytes [%]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil granulocytes [%]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Safety After Oral Intake</condition>
  <condition>Pharmacokinetics After Oral Intake</condition>
  <condition>Immune Cells Activity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules filled with mannitol and silicon dioxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6-prenylnaringenin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg 6-PN plus mannitol and silicon dioxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8-prenylnaringenin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg 8-PN plus mannitol and silicon dioxide</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>6-prenylnaringenin</intervention_name>
    <arm_group_label>6-prenylnaringenin</arm_group_label>
    <other_name>6-PN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>8-prenylnaringenin</intervention_name>
    <arm_group_label>8-prenylnaringenin</arm_group_label>
    <other_name>8-PN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Volunteers with blood chemistry values within normal ranges

          -  Age: 18-45 years

          -  BMI: 19-25 kg/m2

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Alcohol and/or drug abuse

          -  Use of dietary supplements or any medications, except contraceptives

          -  Any known malignant, metabolic and endocrine diseases

          -  Previous cardiac infarction

          -  Dementia

          -  Participation in a clinical trial within the past 6 weeks prior to recruitment

          -  Physical activity of more than 5 h/wk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Frank, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hohenheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sascha Venturelli, Dr. med. Dr. rer. nat.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eberhard Karls University Tuebingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Busch, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eberhard Karls University Tuebingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Hohenheim</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eberhard Karls University Tuebingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.nutrition-research.de/</url>
    <description>Website of the research group</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>8-prenylnaringenin</keyword>
  <keyword>6-prenylnaringenin</keyword>
  <keyword>Prenylflavonoids</keyword>
  <keyword>PBMC</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>8-prenylnaringenin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

